Monique P Curran

Summary

Affiliation: Adis International Inc
Country: USA

Publications

  1. doi request reprint Duloxetine: a review of its use in the management of major depressive disorder in older adults
    Sohita Dhillon
    Adis, 41 Centorian Drive, Mairangi Bay, Private Bag 65901, North Shore, Auckland, New Zealand
    Drugs Aging 30:59-79. 2013
  2. doi request reprint Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU
    Katherine A Lyseng-Williamson
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, New Zealand
    Drugs Aging 30:51-8. 2013
  3. doi request reprint Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years
    Katherine A Lyseng-Williamson
    Adis, Mairangi Bay, North Shore, Auckland, New Zealand
    Drugs Aging 29:911-23. 2012
  4. doi request reprint Aflibercept for intravitreal injection: in neovascular age-related macular degeneration
    James E Frampton
    Adis, Auckland, New Zealand
    Drugs Aging 29:839-46. 2012
  5. doi request reprint Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): a guide to its use in older adults
    Lesley J Scott
    Adis, Auckland, New Zealand
    Drugs Aging 29:847-55. 2012
  6. ncbi request reprint Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction
    Monique P Curran
    Adis, Mairangi Bay, North Shore, Auckland, New Zealand
    Drugs Aging 29:771-81. 2012
  7. ncbi request reprint Letrozole: a review of its use in postmenopausal women with breast cancer
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1213-30. 2004
  8. ncbi request reprint Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure
    Dean M Robinson
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 67:1359-78. 2007
  9. doi request reprint Transdermal granisetron
    Sean T Duggan
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 69:2597-605. 2009
  10. ncbi request reprint Eszopiclone: a review of its use in the treatment of insomnia
    Philip I Hair
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:1415-34. 2008

Collaborators

  • Gillian M Keating
  • Katherine A Lyseng-Williamson
  • Paul L McCormack
  • Greg L Plosker
  • Sohita Dhillon
  • Dene Simpson
  • Lily P H Yang
  • James E Frampton
  • Philip I Hair
  • Lesley J Scott
  • Sean T Duggan
  • Katherine F Croom
  • Susan J Keam
  • Claudine M Chwieduk
  • Mark Sanford
  • Karly P Garnock-Jones
  • Stephanie K A Blick
  • Vanessa R Anderson
  • Dean M Robinson
  • Christopher Dunn
  • Keri Wellington
  • Kate McKeage
  • Caroline M Perry
  • Natalie J Carter
  • Vicki Oldfield
  • Karen L Goa

Detail Information

Publications63

  1. doi request reprint Duloxetine: a review of its use in the management of major depressive disorder in older adults
    Sohita Dhillon
    Adis, 41 Centorian Drive, Mairangi Bay, Private Bag 65901, North Shore, Auckland, New Zealand
    Drugs Aging 30:59-79. 2013
    ....
  2. doi request reprint Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU
    Katherine A Lyseng-Williamson
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, New Zealand
    Drugs Aging 30:51-8. 2013
    ..Memantine is well tolerated, with an adverse event profile that is similar to that with placebo...
  3. doi request reprint Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years
    Katherine A Lyseng-Williamson
    Adis, Mairangi Bay, North Shore, Auckland, New Zealand
    Drugs Aging 29:911-23. 2012
    ..Short- or longer-term treatment with melatonin PR 2 mg was not associated with dependence, tolerance, rebound insomnia or withdrawal symptoms...
  4. doi request reprint Aflibercept for intravitreal injection: in neovascular age-related macular degeneration
    James E Frampton
    Adis, Auckland, New Zealand
    Drugs Aging 29:839-46. 2012
    ..Aflibercept was generally well tolerated in the VIEW studies; the ocular and non-ocular adverse event profile of the drug was similar to that of ranibizumab...
  5. doi request reprint Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): a guide to its use in older adults
    Lesley J Scott
    Adis, Auckland, New Zealand
    Drugs Aging 29:847-55. 2012
    ..The PCV13 vaccine was generally well tolerated in older adults participating in these trials...
  6. ncbi request reprint Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction
    Monique P Curran
    Adis, Mairangi Bay, North Shore, Auckland, New Zealand
    Drugs Aging 29:771-81. 2012
    ..Tadalafil was generally well tolerated (for a period of up to 1 year) in patients with BPH, including those with ED, with adverse events being of mild to moderate intensity...
  7. ncbi request reprint Letrozole: a review of its use in postmenopausal women with breast cancer
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1213-30. 2004
    ..For early-stage disease, letrozole is superior to tamoxifen in the neoadjuvant setting, and prolongs disease-free survival when administered after the standard 5-year period of adjuvant tamoxifen therapy...
  8. ncbi request reprint Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure
    Dean M Robinson
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 67:1359-78. 2007
    ..Imidapril was well tolerated, with a lower incidence of dry cough than enalapril or benazepril, and is a first choice ACE inhibitor for the treatment of mild to moderate essential hypertension...
  9. doi request reprint Transdermal granisetron
    Sean T Duggan
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 69:2597-605. 2009
    ..Transdermal granisetron was generally well tolerated in clinical trials, with few adverse events being treatment related...
  10. ncbi request reprint Eszopiclone: a review of its use in the treatment of insomnia
    Philip I Hair
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:1415-34. 2008
    ..Therefore, eszopiclone is a useful therapeutic option in the management of adult and elderly patients with primary or co-morbid insomnia. Unlike most other hypnotics, eszopiclone is not limited to short-term use...
  11. doi request reprint Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy
    Gillian M Keating
    Adis, Auckland, New Zealand
    CNS Drugs 26:787-90. 2012
    ..Thus, transdermal granisetron provides a convenient option for the prevention of chemotherapy-induced nausea and vomiting, with the potential to improve patient compliance...
  12. ncbi request reprint Spotlight on bupropion in major depressive disorder
    Sohita Dhillon
    Wolters Kluwer Health Adis, Auckland, New Zealand
    CNS Drugs 22:613-7. 2008
    ..Available clinical data suggest that bupropion is an effective and generally well tolerated option in the treatment of MDD, with the newer formulations having the advantage of reduced frequency of daily administration...
  13. ncbi request reprint Alvimopan
    Monique P Curran
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:2011-9. 2008
    ..Alvimopan did not reduce opioid-induced analgesia and/or increase the amount of opioids administered postoperatively. Short-term alvimopan was generally well tolerated in adults undergoing bowel resection...
  14. doi request reprint Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:1411-22. 2010
    ..Most adverse events associated with lapatinib when administered in combination with letrozole were mild to moderate in severity in the EGF30008 phase III trial...
  15. doi request reprint Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension
    Sean T Duggan
    Adis, a Wolters Kluwer Business, Mairangi Bay, North Shore, Auckland, New Zealand
    Drugs 70:2011-49. 2010
    ..Thus, aliskiren is a useful option for the treatment of patients with stage 1 to stage 2 (mild to moderate) hypertension, alone or in combination with other antihypertensives, including HCTZ, valsartan or amlodipine...
  16. ncbi request reprint Tramadol extended-release tablets in moderate to moderately severe chronic pain in adults: profile report
    Philip I Hair
    Wolters Kluwer Health Adis, Auckland, New Zealand
    CNS Drugs 21:259-63. 2007
  17. ncbi request reprint Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    BioDrugs 20:63-5. 2006
    ..Eptifibatide is well tolerated in these trials. Ongoing trials are currently investigating the efficacy and tolerability of regimens that include this agent in other indications, including ST-segment elevation MI...
  18. ncbi request reprint Ramelteon: a review of its use in insomnia
    Dene Simpson
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:1901-19. 2008
    ..Thus, ramelteon provides a well tolerated option for the treatment of patients with insomnia characterized by difficulty in sleep onset...
  19. doi request reprint Spotlight on topical pimecrolimus in pediatric atopic dermatitis
    Lily P H Yang
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Clin Dermatol 11:295-8. 2010
    ....
  20. ncbi request reprint Tramadol extended-release tablets
    Philip I Hair
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 66:2017-27; discussion 2028-30. 2006
    ..Common adverse events reported in patients with moderate to moderately severe chronic pain treated with tramadol ER 100-300 mg once daily were dizziness (excluding vertigo), nausea, constipation, somnolence and flushing...
  21. ncbi request reprint Lumiracoxib
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2237-46; discussion 2247-8. 2004
    ..Lumiracoxib was not associated with an increase in cardiovascular events...
  22. ncbi request reprint Tigecycline
    James E Frampton
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2623-35; discussion 2636-7. 2005
    ....
  23. ncbi request reprint Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease
    Monique P Curran
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:1139-56. 2008
    ....
  24. ncbi request reprint Ropivacaine: a review of its use in regional anaesthesia and acute pain management
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2675-717. 2005
    ....
  25. doi request reprint Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension
    Monique P Curran
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs Aging 26:169-84. 2009
    ....
  26. doi request reprint Bivalirudin: in patients with ST-segment elevation myocardial infarction
    Monique P Curran
    Adis, Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:909-18. 2010
    ....
  27. ncbi request reprint Aliskiren: a review of its use in the management of hypertension
    James E Frampton
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 67:1767-92. 2007
    ..Nonetheless, by offering a new approach to the blockade of the RAS, aliskiren provides a useful addition to the therapeutic options available to treat patients with mild to moderate hypertension...
  28. doi request reprint Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:191-213. 2010
    ..In summary, amlodipine/atorvastatin offers a convenient and effective approach to improving adherence and managing CV risk in hypertensive patients with dyslipidaemia or at risk of CVD...
  29. doi request reprint Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease
    Monique P Curran
    Adis, North Shore, Auckland, New Zealand
    Drugs 69:2329-49. 2009
    ..Overall, lanthanum carbonate is a valuable option for the reduction of serum phosphate levels in patients with ESRD on haemodialysis or peritoneal dialysis...
  30. doi request reprint Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis
    Lily P H Yang
    Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Paediatr Drugs 11:407-26. 2009
    ....
  31. doi request reprint Pramipexole extended release: in Parkinson's disease
    Claudine M Chwieduk
    Adis, a Wolters Kluwer Business, North Shore, Auckland, New Zealand
    CNS Drugs 24:327-36. 2010
    ..Pramipexole ER was generally well tolerated in patients with Parkinson's disease, with the rate of adverse events being generally similar to that with pramipexole IR...
  32. ncbi request reprint Cefditoren pivoxil: a review of its use in the treatment of bacterial infections
    Keri Wellington
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2597-618. 2004
    ....
  33. ncbi request reprint Perindopril: a review of its use in patients with or at risk of developing coronary artery disease
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    Drugs 66:235-55. 2006
    ....
  34. ncbi request reprint Orlistat: a review of its use in the management of patients with obesity
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2845-64. 2004
    ..Orlistat, in addition to lifestyle and dietary intervention, is thus an attractive option for the treatment of patients with obesity, especially those with associated comorbidities or at risk of developing type 2 diabetes...
  35. ncbi request reprint Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    Drugs 66:1755-82. 2006
    ..Potential exists for further investigation of the use of this agent in clinical settings where a vasodilatory agent with minimal inotropic effects is appropriate...
  36. doi request reprint Decitabine: a review of its use in older patients with acute myeloid leukaemia
    Monique P Curran
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    Drugs Aging 30:447-58. 2013
    ..In conclusion, low-dose decitabine may be considered as an effective and generally well tolerated alternative treatment to cytarabine or supportive care in older patients with AML who are not candidates for standard induction therapy...
  37. doi request reprint Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 26:1049-71. 2009
    ..Other adverse events included increases in the pigmentation of the iris, perorbital areas and eyelashes...
  38. ncbi request reprint Mosapride in gastrointestinal disorders
    Monique P Curran
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:981-91. 2008
    ..Mosapride was well tolerated, with diarrhoea/loose stools, dry mouth, malaise and headache being reported in <5% of patients...
  39. ncbi request reprint Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2009-35. 2005
    ..Eptifibatide is well tolerated in these trials. Ongoing trials are currently investigating the efficacy and tolerability of regimens that include this agent in other indications, including ST-segment elevation MI (STEMI)...
  40. ncbi request reprint Oral sodium phosphate solution: a review of its use as a colorectal cleanser
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1697-714. 2004
    ..The decrease in serum potassium levels after administration of oral sodium phosphate solution was negatively correlated with baseline intracellular potassium levels...
  41. ncbi request reprint Cabergoline : a review of its use in the treatment of Parkinson's disease
    Monique P Curran
    Adis International, Auckland, New Zealand
    Drugs 64:2125-41. 2004
    ....
  42. doi request reprint Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Paediatr Drugs 14:51-60. 2012
    ..Everolimus was generally well tolerated in patients with SEGA associated with TSC; most drug-related adverse reactions were mild to moderate in severity...
  43. doi request reprint Crizotinib: in locally advanced or metastatic non-small cell lung cancer
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 72:99-107. 2012
    ..Crizotinib was generally well tolerated, with most adverse reactions being grade 1 or 2. The most commonly reported treatment-related adverse reactions were vision disorder, gastrointestinal disorders and oedema...
  44. doi request reprint Live attenuated influenza vaccine (Fluenz™): a guide to its use in the prevention of seasonal influenza in children in the EU
    Lesley J Scott
    Adis, Auckland, New Zealand
    Paediatr Drugs 14:271-9. 2012
    ....
  45. ncbi request reprint Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra)
    Sohita Dhillon
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Paediatr Drugs 10:337-47. 2008
    ..Injection-site redness and fever (rectal temperature > or =38degreesC or axillary temperature > or =37.5degreesC) were the most frequent adverse events in both groups...
  46. ncbi request reprint Tacrolimus: in patients with rheumatoid arthritis
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    Drugs 65:993-1001; discussion 1002-3. 2005
    ....
  47. ncbi request reprint Bupropion: a review of its use in the management of major depressive disorder
    Sohita Dhillon
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:653-89. 2008
    ..Available clinical data suggest that bupropion is an effective and generally well tolerated option in the treatment of MDD, with the newer formulations having the advantage of reduced frequency of daily administration...
  48. ncbi request reprint Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy
    Katherine F Croom
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 64:999-1028. 2004
    ..Thus, irbesartan is a valuable agent in the management of patients with these indications...
  49. doi request reprint Aprepitant: a review of its use in the prevention of nausea and vomiting
    Monique P Curran
    Wolters Kluwer Health, Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 69:1853-78. 2009
    ..Aprepitant was generally well tolerated. Aprepitant is a recommended option for the treatment of PONV, and when combined with a corticosteroid and 5-HT(3) receptor antagonist is a recommended regimen for the treatment of CINV...
  50. ncbi request reprint Temsirolimus: in advanced renal cell carcinoma
    Dene Simpson
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:631-8. 2008
    ..8% in IFNalpha recipients. Temsirolimus monotherapy recipients experienced significantly fewer grade 3 or 4 adverse events and had numerically fewer withdrawals for adverse events than patients receiving IFNalpha...
  51. ncbi request reprint Sildenafil: a review of its use in pulmonary arterial hypertension
    Katherine F Croom
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:383-97. 2008
    ..In conclusion, sildenafil is an effective oral treatment option for patients with PAH...
  52. ncbi request reprint Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy
    Kate McKeage
    Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 64:633-48. 2004
    ..Thus, fulvestrant provides an effective and well tolerated option for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy...
  53. doi request reprint Regadenoson
    Karly P Garnock-Jones
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Cardiovasc Drugs 10:65-71. 2010
    ..No unexpected treatment-emergent ECG changes occurred with regadenoson in the phase III trials...
  54. ncbi request reprint Certolizumab pegol: in Crohn's disease
    Stephanie K A Blick
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 21:195-201; discussion 202-3. 2007
    ..Certolizumab pegol was, in general, well tolerated, and adverse events associated with the drug were of a mild to moderate nature; no instances of lupus were reported in any of the trials...
  55. doi request reprint Bortezomib: a review of its use in patients with multiple myeloma
    Monique P Curran
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 69:859-88. 2009
    ....
  56. ncbi request reprint Inhaled human insulin (Exubera): a review of its use in adult patients with diabetes mellitus
    Christopher Dunn
    Adis International Limited, 51 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 66:1013-32. 2006
    ..It is also well tolerated and effective in patients with type 2 diabetes when administered alone, when combined with oral antihyperglycaemic therapy, or when combined with basal subcutaneous insulin...
  57. doi request reprint Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 28:843-5. 2011
  58. doi request reprint Niacin extended-release/simvastatin
    Mark Sanford
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:2373-86. 2008
    ..Niacin ER/simvastatin was generally well tolerated, with flushing being the most common adverse reaction...
  59. doi request reprint Duloxetine: in patients with fibromyalgia
    Monique P Curran
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 69:1217-27. 2009
    ..Duloxetine was generally well tolerated in studies of up to 1 year in duration, with nausea being the most frequent adverse event and main cause for discontinuing therapy...
  60. ncbi request reprint Spotlight on verteporfin in subfoveal choroidal neovascularisation
    Susan J Keam
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 21:203-9. 2004
    ..Approximately 5% of patients with occult with no classic subfoveal CNV secondary to AMD reported severe vision decrease within 7 days of treatment in clinical trials; 3 months later, several patients had recovered some of this loss...
  61. ncbi request reprint Nitazoxanide: a review of its use in the treatment of gastrointestinal infections
    Vanessa R Anderson
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 67:1947-67. 2007
    ..parvum or G. lamblia infection in immunocompetent adults and children, and is an option to be considered in the treatment of illnesses caused by other protozoa and/or helminths...
  62. doi request reprint Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia
    Monique P Curran
    Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 71:897-907. 2011
    ..Abnormal ejaculation, a class effect of α(1A)-adrenoceptor antagonists, was the most common silodosin-associated adverse reaction, but resulted in treatment withdrawal of only a limited number of patients...
  63. doi request reprint Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Paediatr Drugs 13:197-204. 2011
    ..Aripiprazole was associated with weight gain in both the short- and long-term studies; data from the long-term study indicated that the increase in bodyweight reached a plateau at 3-6 months...